Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Trial Profile

Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Mesothelioma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Jun 2016 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 02 Jun 2016 Planned primary completion date changed from 1 Feb 2018 to 1 May 2018.
    • 02 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top